Plant ID: NPO21424
Plant Latin Name: Garcinia xanthochymus
Taxonomy Genus: Garcinia
Taxonomy Family: Clusiaceae
NCBI TaxonomyDB:
198766
Plant-of-the-World-Online:
1164363-2
Australia; Bangladesh; Myanmar; India; Cambodia; Trinidad and Tobago; Vietnam; China; Laos; Thailand; Fiji
OPRD1; | |
DRD3; HTR2C; | |
PTPN1; | |
MTOR; PKM; ALOX15; POLB; APEX1; | |
MAOA; | |
BACE1; | |
HIF1A; TP53; NFKB1; STAT6; | |
EP300; | |
VCP; | |
HTT; LMNA; MCL1; THPO; | |
SMN1;SMN2; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
Bromodomain | EP300 | Histone acetyltransferase p300 | Q09472 | CHEMBL3784 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Endoplasmic reticular retrotranslocon family | VCP | Transitional endoplasmic reticulum ATPase | P55072 | CHEMBL1075145 |
Enzyme_unclassified | MTOR | Serine/threonine-protein kinase mTOR | P42345 | CHEMBL2842 |
Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
Peptide receptor (family A GPCR) | OPRD1 | Delta opioid receptor | P41143 | CHEMBL236 |
Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
Small molecule receptor (family A GPCR) | DRD3 | Dopamine D3 receptor | P35462 | CHEMBL234 |
Small molecule receptor (family A GPCR) | HTR2C | Serotonin 2c (5-HT2c) receptor | P28335 | CHEMBL225 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | MCL1 | Induced myeloid leukemia cell differentiation protein Mcl-1 | Q07820 | CHEMBL4361 |
Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 4.531E-11 | 9.867E-07 | CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 3.017E-07 | 6.570E-04 | HIF1A, LMNA, MTOR, OPRD1, TP53 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 5.313E-07 | 6.806E-04 | CYP1A2, CYP2C19, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 5.313E-07 | 6.806E-04 | CYP1A2, CYP2D6, CYP3A4 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 4.337E-07 | 6.806E-04 | CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
BP | GO:0009987; cellular process | GO:0097237; cellular response to toxic substance | 6.158E-07 | 7.450E-04 | APEX1, NFKB1, OPRD1, STAT6, TP53 |
BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 1.882E-06 | 1.576E-03 | APEX1, POLB |
BP | GO:0009987; cellular process | GO:0008630; intrinsic apoptotic signaling pathway in response to DNA damage | 2.319E-06 | 1.629E-03 | EP300, MCL1, POLB, TP53 |
MF | GO:0005488; binding | GO:0003684; damaged DNA binding | 2.185E-06 | 1.629E-03 | APEX1, EP300, POLB, TP53 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.552E-06 | 1.719E-03 | ALOX15, CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
MF | GO:0005488; binding | GO:0002039; p53 binding | 2.606E-06 | 1.719E-03 | EP300, HIF1A, HTT, TP53 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 4.234E-06 | 2.634E-03 | CYP1A2, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 5.640E-06 | 3.149E-03 | CYP2D6, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.127E-05 | 4.508E-03 | CYP1A2, CYP3A4 |
MF | GO:0005488; binding | GO:0008134; transcription factor binding | 1.248E-05 | 4.669E-03 | APEX1, EP300, HIF1A, HTT, MTOR, NFKB1, TP53 |
MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 1.416E-05 | 4.973E-03 | CYP2C19, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 1.819E-05 | 5.577E-03 | CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
MF | GO:0005488; binding | GO:0019903; protein phosphatase binding | 2.083E-05 | 6.030E-03 | PTPN1, STAT6, TP53, VCP |
BP | GO:0032502; developmental process | GO:0048856; anatomical structure development | 2.840E-05 | 7.349E-03 | ALOX15, CYP1A2, EP300, HIF1A, HTT, LMNA, MCL1, MTOR, PKM, POLB, SMN1, SMN2, THPO, TP53 |
MF | GO:0005488; binding | GO:0020037; heme binding | 2.869E-05 | 7.349E-03 | CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
BP | GO:0050896; response to stimulus | GO:0010035; response to inorganic substance | 3.500E-05 | 8.760E-03 | ALOX15, APEX1, CYP1A2, HIF1A, STAT6, TP53 |
BP | GO:0008152; metabolic process | GO:1903715; regulation of aerobic respiration | 3.934E-05 | 9.181E-03 | HIF1A, VCP |
BP | GO:0009987; cellular process | GO:1902533; positive regulation of intracellular signal transduction | 3.963E-05 | 9.181E-03 | ALOX15, HTR2C, HTT, MCL1, MTOR, PTPN1, THPO, TP53 |
MF | GO:0005488; binding | GO:0042802; identical protein binding | 3.939E-05 | 9.181E-03 | HTT, MCL1, MTOR, NFKB1, PKM, SMN1, SMN2, STAT6, TP53, VCP |
BP | GO:0007610; behavior | GO:0008542; visual learning | 4.039E-05 | 9.235E-03 | DRD3, HIF1A, MTOR |
BP | GO:0008152; metabolic process | GO:0016579; protein deubiquitination | 4.107E-05 | 9.235E-03 | EP300, HIF1A, POLB, TP53, VCP |
BP | GO:0008152; metabolic process | GO:0032787; monocarboxylic acid metabolic process | 4.283E-05 | 9.235E-03 | ALOX15, CYP1A2, CYP2C19, CYP2D6, HIF1A, PKM |
CC | GO:0044464; cell part | GO:0042995; cell projection | 7.119E-05 | 1.250E-02 | BACE1, DRD3, HIF1A, HTT, MTOR, OPRD1, PKM, SMN1, SMN2 |
CC | GO:0043226; organelle | GO:0043231; intracellular membrane-bounded organelle | 1.033E-04 | 1.631E-02 | APEX1, BACE1, CYP1A2, CYP2C19, CYP2D6, CYP3A4, EP300, HIF1A, HTT, LMNA, MAOA, MCL1, MTOR, NFKB1, PKM, POLB, PTPN1, SMN1, SMN2, TP53, VCP |
CC | GO:0043226; organelle | GO:0097504; Gemini of coiled bodies | 1.231E-04 | 1.836E-02 | SMN1, SMN2 |
CC | GO:0032991; macromolecular complex | GO:0032797; SMN complex | 1.454E-04 | 2.051E-02 | SMN1, SMN2 |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 3.210E-08 | 3.820E-06 | MAOA, CYP2D6, CYP1A2, CYP3A4, CYP2C19 |
09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 6.112E-08 | 3.820E-06 | CYP1A2, ALOX15, CYP3A4, CYP2C19 |
09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 3.683E-07 | 1.535E-05 | CYP2D6, MAOA, ALOX15, HTR2C, CYP2C19 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04630 | Jak-STAT signaling pathway | 2.026E-06 | 5.065E-05 | THPO, EP300, STAT6, MTOR, MCL1 |
09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 1.905E-06 | 5.065E-05 | PKM, TP53, HIF1A, MTOR |
09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 5.946E-06 | 1.239E-04 | EP300, TP53, NFKB1, MTOR |
09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 7.240E-06 | 1.293E-04 | POLB, PKM, EP300, TP53, NFKB1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 1.063E-05 | 1.661E-04 | EP300, HIF1A, NFKB1, MTOR |
09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 1.819E-05 | 2.527E-04 | EP300, TP53, HIF1A, MTOR |
09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 3.562E-05 | 4.452E-04 | LMNA, TP53, NFKB1, MCL1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 4.197E-05 | 4.491E-04 | EP300, STAT6, TP53, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 4.311E-05 | 4.491E-04 | EP300, TP53, NFKB1, MTOR, MCL1 |
09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 1.692E-04 | 1.508E-03 | EP300, HIF1A, TP53, NFKB1, MTOR |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 1.281E-04 | 1.232E-03 | CYP2D6, CYP1A2, CYP3A4 |
09150 Organismal Systems | 09149 Aging | hsa04211 | Longevity regulating pathway - mammal | 2.710E-04 | 2.117E-03 | TP53, NFKB1, MTOR |
09160 Human Diseases | 09167 Infectious diseases | hsa05166 | HTLV-I infection | 3.759E-04 | 2.764E-03 | POLB, EP300, TP53, NFKB1 |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04931 | Insulin resistance | 4.187E-04 | 2.908E-03 | PTPN1, NFKB1, MTOR |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 1.810E-04 | 1.508E-03 | CYP1A2, CYP3A4, CYP2C19 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 1.069E-03 | 6.361E-03 | TP53, NFKB1, MTOR, MCL1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 5.546E-04 | 3.649E-03 | OPRD1, TP53, NFKB1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05168 | Herpes simplex infection | 1.934E-03 | 9.924E-03 | EP300, TP53, NFKB1 |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04930 | Type II diabetes mellitus | 1.905E-03 | 9.924E-03 | PKM, MTOR |
09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 1.326E-03 | 7.536E-03 | MAOA, CYP1A2 |
09160 Human Diseases | 09164 Substance dependence | hsa05030 | Cocaine addiction | 1.985E-03 | 9.924E-03 | MAOA, NFKB1 |
09120 Genetic Information Processing | 09124 Replication and repair | hsa03410 | Base excision repair | 9.031E-04 | 5.644E-03 | POLB, APEX1 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
I00-I99: Diseases of the circulatory system | Ischemic heart diseases | I20-I25 | OPRD1; |
NA: NA | Acute nonspecific diarrhea | NA | OPRD1; |
G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | OPRD1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; MAOA; OPRD1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA; OPRD1; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Premature ejaculation | F52.4 | OPRD1; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Moderate-to-severe pain | R52, G89 | OPRD1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA; |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MAOA; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | OPRD1; |
C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | OPRD1; |
K00-K95: Diseases of the digestive system | Diarrhea-predominant IBS | K58.0 | OPRD1; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | OPRD1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; OPRD1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA; |
A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6; |
NA: NA | Chronic diarrhea associated with inflammatory bowel disease | NA | OPRD1; |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; |
G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | OPRD1; |
G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6; |
N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | OPRD1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; |
N00-N99: Diseases of the genitourinary system | Bladder disease | N30-N32 | OPRD1; |